Skip to main content

VectivBio Holding AG (VECT)

NASDAQ: VECT · Delayed Price · USD
7.42 0.03 (0.41%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap252.39M
Revenue (ttm)n/a
Net Income (ttm)-59.94M
Shares Out34.01M
EPS (ttm)-1.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,176
Open7.33
Previous Close7.39
Day's Range7.28 - 7.54
52-Week Range6.69 - 37.70
Betan/a
AnalystsStrong Buy
Price Target25.50 (+243.7%)
Est. Earnings Daten/a

About VECT

VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product candidate, apraglutide, i...

IndustryBiotechnology
IPO DateApr 9, 2021
Stock ExchangeNASDAQ
Ticker SymbolVECT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VECT stock is "Strong Buy." The 12-month stock price forecast is 25.50, which is an increase of 243.67% from the latest price.

Price Target
$25.50
(243.67% upside)
Analyst Consensus: Strong Buy

News

VectivBio Announces Closing of Comet Therapeutics Acquisition

- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - - Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases -

2 days ago - GlobeNewsWire

VectivBio Announces Upcoming Investor Events

Company to host an R&D Day on September 21, 2021 Company to host an R&D Day on September 21, 2021

1 week ago - GlobeNewsWire

VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary

Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities

2 weeks ago - GlobeNewsWire

VectivBio Announces Results of Extraordinary General Meeting

Paul R. Carter and Murray W. Stewart Elected to the Board of Directors Paul R. Carter and Murray W. Stewart Elected to the Board of Directors

2 weeks ago - GlobeNewsWire

VectivBio to Acquire Comet Therapeutics and Host R&D Day

- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021-

3 weeks ago - GlobeNewsWire

VectivBio Publishes Invitation to the Extraordinary General Meeting

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

1 month ago - GlobeNewsWire

VectivBio Nominates Paul R. Carter and Murray W.

- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on Sep...

2 months ago - GlobeNewsWire

VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease

Phase 2 trial expected to begin in the first quarter of 2022 Phase 2 trial expected to begin in the first quarter of 2022

2 months ago - GlobeNewsWire

VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients wit...

Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population...

3 months ago - GlobeNewsWire

VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer

Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of a...

3 months ago - GlobeNewsWire

CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of t...

5 months ago - GlobeNewsWire

VectivBio Announces Closing of $146.6 Million Initial Public Offering

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...

5 months ago - GlobeNewsWire

Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...

Other symbols:RPHM
5 months ago - InvestorPlace

VectivBio Announces Pricing of Initial Public Offering

VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical...

5 months ago - GlobeNewswire

Swiss rare disease biotech VectivBio Holding files for a $100 million US IPO

VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

VectivBio Holding IPO Registration Document (S-1)

VectivBio Holding AG has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC